Alain Huriez
Fondateur chez Luxfold S.A.
Profil
Alain Huriez is the founder of Luxfold S.A.
(founded in 2013), Tc Land Expression SA (founded in 2002), and AdBio Partners SAS (founded in 2015).
He held the title of Chairman & Chief Executive Officer at Tc Land Expression SA from 2009 to 2012.
He is currently the Chairman at Urania Therapeutics SAS, Director at Tridek-One Therapeutics SAS, Alderaan Biotechnology SAS, Augustine Therapeutics NV, DiogenX SAS, and Venture Partner at Advent Venture Partners LLP (since 2012).
Dr. Huriez previously served as Chairman & Chief Executive Officer at Neovacs SA and Chairman at Orphalan SA from 2015 to 2022.
He holds a graduate degree and an MBA from Université Paris Diderot-Paris 7.
Postes actifs de Alain Huriez
| Sociétés | Poste | Début |
|---|---|---|
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 01/01/2012 |
Luxfold S.A.
 Luxfold S.A. BiotechnologyHealth Technology Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg. | Fondateur | 11/07/2013 |
AdBio Partners SAS
 AdBio Partners SAS Investment ManagersFinance AdBio Partners SAS (AdBio Partners) is a venture capital firm founded in 2015. The firm is headquartered in Paris, France. | Fondateur | 25/11/2015 |
Alderaan Biotechnology SAS
 Alderaan Biotechnology SAS BiotechnologyHealth Technology Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France. | Directeur/Membre du Conseil | - |
Urania Therapeutics SAS
 Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Président | - |
Augustine Therapeutics NV
 Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Directeur/Membre du Conseil | - |
DiogenX SAS
 DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Directeur/Membre du Conseil | - |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Directeur/Membre du Conseil | - |
Anciens postes connus de Alain Huriez
| Sociétés | Poste | Fin |
|---|---|---|
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Président | - |
| ░░ ░░░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░ | - |
Formation de Alain Huriez
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEOVACS | Health Technology |
| Entreprise privées | 11 |
|---|---|
| Université Paris Diderot-Paris 7 | Consumer Services |
Tc Land Expression SA
 Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Commercial Services |
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
Luxfold S.A.
Luxfold S.A. BiotechnologyHealth Technology Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg. | Health Technology |
Orphalan SA
Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Health Technology |
AdBio Partners SAS
AdBio Partners SAS Investment ManagersFinance AdBio Partners SAS (AdBio Partners) is a venture capital firm founded in 2015. The firm is headquartered in Paris, France. | Finance |
Alderaan Biotechnology SAS
Alderaan Biotechnology SAS BiotechnologyHealth Technology Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France. | Health Technology |
Urania Therapeutics SAS
Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Health Technology |
Augustine Therapeutics NV
Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Health Services |
DiogenX SAS
DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Health Technology |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |